Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/198662
Title: | Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis |
Author: | Lleixà, Cinta Caballero Ávila, Marta Pascual Goñi, Elba Martín Aguilar, Lorena Vidal, Nuria Tejada, Clara Valdés Hevia, Eduardo Zárate, Elisa Vesperinas, Ana Collet, Roger Franco Leyva, Teresa Martínez Martínez, Laura Moga, Esther Cortés Vicente, Elena Rojas García, Ricard Gómez Anson, Beatriz Gil, Anna González Mingot, Cristina Brieva, Luis Martínez Yélamos, Sergio Querol, Luis |
Keywords: | Esclerosi múltiple Antígens Multiple sclerosis Antigens |
Issue Date: | 2-Mar-2023 |
Publisher: | Oxford University Press (OUP) |
Abstract: | Lleixa and Caballero-avila et al. report that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. Multiple sclerosis is a tissue-specific autoimmune disease of the central nervous system in which the antigen(s) remains elusive. Antibodies targeting the flotillin-1/2 complex have been described in 1-2% of the patients in a recent study. Other candidate antigens as anoctamin-2 or neurofascin-155 have been previously described in multiple sclerosis patients, although their clinical relevance remains uncertain. Our study aims to analyse the frequency and clinical relevance of antibodies against neurofascin-155, anoctamin-2 and flotillin-1/2 complex in multiple sclerosis. Serum (n = 252) and CSF (n = 50) samples from 282 multiple sclerosis patients were included in the study. The control group was composed of 260 serum samples (71 healthy donors and 189 with other neuroinflammatory disorders). Anti-flotillin-1/2, anti-anoctamin-2 and anti-neurofascin-155 antibodies were tested by cell-based assays using transfected cells. We identified six multiple sclerosis patients with antibodies against the flotillin-1/2 complex (2.1%) and one multiple sclerosis patient with antibodies against anoctamin-2 (0.35%). All multiple sclerosis patients were negative for anti-neurofascin-155 antibodies. Three of the anti-flotillin-1/2 positive patients showed anti-flotillin-1/2 positivity in other serum samples extracted at different moments of their disease. Immunoglobulin G subclasses of anti-flotillin-1/2 antibodies were predominantly one and three. We confirm that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. |
Note: | Reproducció del document publicat a: https://doi.org/10.1093/braincomms/fcad109 |
It is part of: | Brain Communications, 2023, vol. 5, num. 2 |
URI: | http://hdl.handle.net/2445/198662 |
Related resource: | https://doi.org/10.1093/braincomms/fcad109 |
ISSN: | 2632-1297 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fcad109.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License